Author

L. Pimenov

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Hladik· 2 shared G. Wirnsberger· 2 shared J. M. Penninger· 2 shared R. Gawish· 2 shared S. Knapp· 2 shared A. Bergthaler· 1 shared A. Hagelkruys· 1 shared A. Mirazimi· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

A. Hladik

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Development of a novel, pan-variant aerosol intervention for COVID-19

R. H. Shoemaker, R. A. Panettieri, S. K. Libutti, H. S. Hochster, N. R. Watts, P. T. Wingfield, P. M. Starkl, L. Pimenov, R. Gawish, A. Hladik, S. Knapp, D. Boring, J. M. White, Q. Lawrence, J. Boone, , G. Wirnsberger

This paper reports preclinical development and evaluation of aerosolized soluble recombinant human ACE2 (APN01) as a COVID-19 intervention.

bioRxiv · Sep 14, 2021 · PreprintPharmacology & Toxicology

ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology

R. Gawish, P. Starkl, L. Pimenov, A. Hladik, K. Lakovits, F. Oberndorfer, S. J. F. Cronin, A. Ohradanova-Repic, G. Wirnsberger, B. Agerer, L. Endler, T. Capraz, J. W. Perthold, A. Hagelkruys, N. Montserrat, , S. Knapp

This paper develops a mouse-adapted SARS-CoV-2 strain, maVie16, to model COVID-19 in mice, showing that ACE2 is critical for disease and that blocking TNF/IFNγ reduces immunopathology.

bioRxiv · Aug 9, 2021Immunology